TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.

臺大醫院-腫瘤醫學部;臺大醫學院-腫瘤醫學研究所;臺大醫學院-癌症研究中心;Yang, James Chih-HsinJames Chih-HsinYangPopat, SanjaySanjayPopatGeorgiou, PanosPanosGeorgiouMiyamoto, EmikoEmikoMiyamotoIsaacson, Jeffrey D.Jeffrey D.IsaacsonWakelee, Heather A.Heather A.Wakelee2017-06-272018-07-092017-06-272018-07-092015http://ntur.lib.ntu.edu.tw//handle/246246/280106[SDGs]SDG3TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.